Recently, immunotherapy targeting the PD1/PD-L1 axis has emerged as promising field in anti-cancer therapy for various tumour entities (including non-small lung cancer, renal cell cancer, or head and neck squamous cell cancer) [5]. This evidence concerns the gene CD274 and cancer.